Pettee Investors Inc. continued to hold its position in Amgen, Inc. (NASDAQ:AMGN) during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,168 shares of the medical research company’s stock at the close of the 1st quarter. Pettee Investors Inc.’s holdings in Amgen were worth $848,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in the business. Swiss National Bank boosted its holdings in shares of Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after buying an additional 551,600 shares during the last quarter. Morningstar Investment Services LLC raised its stake in Amgen by 283.8% during the 1st quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock worth $81,625,000 after acquiring an additional 367,894 shares during the period. Karp Capital Management Corp bought a new stake in Amgen during the 1st quarter worth approximately $54,888,000. State of Tennessee Treasury Department raised its stake in Amgen by 51.4% during the 1st quarter. State of Tennessee Treasury Department now owns 783,570 shares of the medical research company’s stock worth $128,560,000 after acquiring an additional 265,931 shares during the period. Finally, Canada Pension Plan Investment Board raised its stake in Amgen by 31.9% during the 1st quarter. Canada Pension Plan Investment Board now owns 1,029,961 shares of the medical research company’s stock worth $168,986,000 after acquiring an additional 248,900 shares during the period. Institutional investors and hedge funds own 78.14% of the company’s stock.
Several equities research analysts have recently issued reports on AMGN shares. Royal Bank Of Canada assumed coverage on shares of Amgen in a research report on Thursday. They issued a “sector perform” rating and a $192.00 price target on the stock. Cann restated a “buy” rating and issued a $203.00 price target (up previously from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. BMO Capital Markets cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Deutsche Bank AG restated a “hold” rating and issued a $174.00 price target (up previously from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $203.00 price objective (up from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $186.14.
Amgen, Inc. (NASDAQ:AMGN) traded down 1.04% during trading on Friday, hitting $187.47. 5,348,992 shares of the stock traded hands. The company’s 50 day moving average price is $175.31 and its 200 day moving average price is $169.32. The company has a market cap of $136.79 billion, a P/E ratio of 17.08 and a beta of 1.35. Amgen, Inc. has a 12 month low of $133.64 and a 12 month high of $191.10.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 27.67% and a net margin of 37.02%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same period last year, the company posted $2.84 EPS. On average, equities research analysts anticipate that Amgen, Inc. will post $12.57 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a $1.15 dividend. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.45%. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
ILLEGAL ACTIVITY WARNING: This story was first posted by BBNS and is owned by of BBNS. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/pettee-investors-inc-maintains-position-in-amgen-inc-amgn/1565930.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.